BridgeBio's ATTR-CM Trial Demonstrates Significant Mortality and Hospitalization Reduction

BridgeBio has announced positive results from its Phase III trial of aco­ramidis in patients with transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM). The trial showed improvements in mortality, cardiovascular-related hospitalizations, a six-minute walk test, and a biomarker of the disease. Patients receiving the drug had an 81% survival rate at 30 months, compared to 74% on placebo, and the drug reduced hospitalization rates by 50%.